New call-to-action
New call-to-action
New call-to-action

Foundation for Prader-Willi Blog | News (4)

Categories

Aardvark IPO Brings $94M to PWS Drug Development

Aardvark Therapeutics achieved a major milestone last week by launching its initial public offering (IPO) and joining the NASDAQ as a publicly traded company (ticker symbol AARD). This marks an exciting step forward for Aardvark and for the entire Pr...
February 17, 2025 Read More

Topics: News

United in Hope: 2025 Global Prader-Willi Syndrome Conference

We are excited to announce that the 2025 "United in Hope" conference will be held in collaboration with the International Prader-Willi Syndrome Organisation (IPWSO), the Prader-Willi Syndrome Association | USA (PWSA | USA), and the Foundation for Pra...
October 16, 2024 Read More

Topics: News, Family Conference

FDA Determines No Need For Advisory Committee Meeting At This Time

Soleno Therapeutics announced today that the U.S. Food and Drug Administration (FDA) Review Division has determined that there does not appear to be a need for an advisory committee meeting at this time for the New Drug Application (NDA) for DCCR (di...
October 8, 2024 Read More

Topics: News

Harvesting Hope: Trot With Us To Make a Difference!

This fall, join us for a heartwarming and impactful challenge: Harvesting Hope—a fun, family-friendly distance challenge that supports Prader-Willi and Schaaf-Yang syndrome research.
October 3, 2024 Read More

Topics: News

Select Sessions from our 2024 Research Symposium and Family Conference Now Available

We're excited to announce that select sessions from our recent PWS Research Symposium and Family Conference are now available to watch! This year’s event brought together leading experts, researchers, and families from around the world to explore the...
October 2, 2024 Read More

Topics: News, Family Conference

FDA Accepts DCCR Filing and Grants Priority Review

Soleno Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) and granted priority review for DCCR (Diazoxide Choline Controlled-Release), a treatment for patients with Prader-Willi...
August 27, 2024 Read More

Topics: News

PWS Advocacy Coalition Submits Petition to FDA for Priority Review of DCCR NDA

On Friday, August 2nd, the PWS Advocacy Coalition submitted a petition to the U.S. Food and Drug Administration (FDA), requesting the filing and priority review of the New Drug Application (NDA) for Soleno Therapeutics’ drug, DCRR. The petition signe...
August 5, 2024 Read More

Topics: News

FDA Grants Rare Pediatric Disease Designation to CSTI-500

The FDA has granted Rare Pediatric Disease Designation (RPDD) to ConSynance Therapeutics' new investigational drug, CSTI-500 for the treatment of Prader-Willi Syndrome in children and adolescents. This special status is granted to drugs and biologics...
July 26, 2024 Read More

Topics: News

Announcing the FPWR Olympics!

Just like the elite athletes competing in the Olympic Games, our community is passionate, dedicated, and persistent in their pursuit of victory! As our Olympians aim for gold, we are relentlessly working towards treatments for Prader-Willi and Schaaf...
July 3, 2024 Read More

Topics: News

About FPWR

The Foundation for Prader-Willi Research (federal tax id 31-1763110) is a nonprofit corporation with federal tax exempt status as a public charity under section 501(c)(3).

4star120x60

NORD_MembershipLogo_Platinum_2021

excellence-in-giving-logo

Main Menu

Our Mission

The mission of FPWR is to eliminate the challenges of Prader-Willi syndrome through the advancement of research and therapeutic development.

Contact Us

Foundation for Prader-Willi Research
Phone: 888-322-5487
Email: info@fpwr.org

FPWR
440 N Barranca Ave #3620
Covina, CA 91723

Copyright © 2020. All Rights Reserved. Terms of Use. Privacy Policy. Copyright Infringement Policy. Disclosure Statement.